August 1, 2023, Opinion: "In 1992, the Food and Drug Administration (FDA) initiated the Accelerated Approval Program to “allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need” based on research using a surrogate endpoint to demonstrate a drug’s effectiveness. After approval, drug companies are still expected to conduct confirmatory trials aimed at showing that the drug does in fact provide a clinical benefit." Read Via Health Affairs